Becton, Dickinson and Company
One Becton Drive
587 articles with Becton, Dickinson and Company
Venovo™ Venous Stent proven safe and effective in iliac and femoral veins
VIVA Physicians Selects NAMSA as Statistical Analytic Group to Evaluate the Safety of Paclitaxel Drug-Eluting Technologies in PAD
VIVA Physicians announced the selection of NAMSA as the independent statistical analysis group to examine individual patient-level data associated with paclitaxel-coated balloons and stent trials used in the treatment of peripheral artery disease in the superficial femoral artery.
BD, a leading global medical technology company, announced that it will present at the Barclays Global Healthcare Conference on Tuesday, March 12, 2019, at 2:05 p.m. ET.
As reported, revenues of $4.160 billion increased 35.1 percent.
BD Nano™ Second Generation Pen Needle Receives 510(k) Clearance from U.S. Food and Drug Administration
The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.77 per common share, payable on March 29, 2019 to holders of record on March 8, 2019.
- Preliminary reported revenues of $4.160 billion increased 35.1 percent. - On a comparable, currency-neutral basis, preliminary revenues increased 5.2 percent. - As reported, preliminary diluted earnings per share of $2.05 increased 369.7 percent. - As adjusted, preliminary diluted earnings per share of $2.70 increased 8.9 percent, or 14.9 percent on a currency-neutral basis. - The company reaffirms previously issued fiscal year 2019 revenue and adjusted
BD (Becton, Dickinson and Company) announced today that it will host a live webcast of its Annual Meeting of Shareholders on Tuesday, January 22, 2019, at 1 p.m. (ET).
BD (Becton, Dickinson and Company) announced today that it will conduct a live webcast of its first fiscal quarter 2019 earnings conference call on Tuesday, February 5, 2019, at 8:00 a.m. (ET). BD will issue a press release detailing the quarter's earnings earlier that morning.
BD (Becton, Dickinson and Company) announced that it will present at the following upcoming investor healthcare conferences
BD MAX™ Enteric Viral Panel Receives 510(k) Clearance from U.S. Food and Drug Administration
BD FACSLyric™ Flow Cytometer is First BD Product to Earn UL Cybersecurity Assurance Program Certification
Learn how advanced analytics can help combat a critical component of the opioid epidemic at the #ASHP18 Midyear Meeting
New Diagnostic Test Helps Hospitals More Quickly Identify and Treat Emerging Antibiotic-Resistant Bacteria
Fully-automated BD Phoenix™ CPO Detect Test Receives U.S. FDA Clearance.
BD (Becton, Dickinson and Company) announced today that it will present at the Stifel 2018 Healthcare Conference on Wednesday, November 14, 2018, at 11:45 AM ET.
- As reported, full fiscal year revenues of $15.983 billion increased 32.2 percent.
Thermo Fisher Scientific Inc. today completed its previously announced acquisition of the Advanced Bioprocessing business from BD (Becton, Dickinson and Company – NYSE: BDX), a leading global medical technology company, for $477 million in cash, subject to post-closing adjustments. The business will be integrated into Thermo Fisher's Life Sciences Solutions Segment.
Brings Total Company Investment in Nebraska to $340 Million in Two Years
Company Joins Effort Alongside Rotary and Leading Global Health Organizations to Expand Vaccinations in India
BD MAX™ MDR-TB Panel Obtains CE-IVD Status in Europe